ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer

ClinicalTrials.gov ID: NCT02258659

Public ClinicalTrials.gov record NCT02258659. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial

Study identification

NCT ID
NCT02258659
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
University of Chicago
Other
Enrollment
62 participants

Conditions and interventions

Interventions

  • carboplatin Drug
  • cisplatin Drug
  • fluorouracil Drug
  • hydroxyurea Drug
  • laboratory biomarker analysis Other
  • paclitaxel Drug
  • paclitaxel albumin-stabilized nanoparticle formulation Drug
  • quality-of-life assessment Procedure
  • radiation therapy Radiation

Drug · Other · Procedure + 1 more

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 21, 2014
Primary completion
Sep 5, 2024
Completion
Sep 5, 2024
Last update posted
Sep 23, 2024

2014 – 2024

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
University of Chicago Chicago Illinois 60637

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02258659, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 23, 2024 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02258659 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →